SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006; 20: 1645-1654.
  • 2
    Jacobson LP, Yamashita TE, Detels R, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 1999; 21( suppl 1): S34-S41.
  • 3
    Jones JL, Hanson DL, Dworkin MS, et al. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. J Acquir Immune Defic Syndr. 2000; 24: 270-274.
  • 4
    Sparano JA, Anand K, Desai J, et al. Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies at an urban medical center. J Acquir Immune Defic Syndr. 1999; 21( suppl 1): S18-S22.
  • 5
    Carrieri MP, Pradier C, Piselli P, et al. Reduced incidence of Kaposi's sarcoma and of systemic non-Hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy. Int J Cancer. 2003; 103: 142-144.
  • 6
    Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol. 2004; 22: 399-402.
  • 7
    International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000; 92: 1823-1830.
  • 8
    Maurer T, Ponte M, Leslie K. HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load [letter]. N Engl J Med. 2007; 357: 1352-1353.
  • 9
    Krown SE, Lee JY, Dittmer DP; AIDS Malignancy Consortium. More on HIV-associated Kaposi's sarcoma [letter]. N Engl J Med. 2008; 358: 535-536.
  • 10
    Mosam A, Carrara H, Shaik F, et al. Increasing incidence of Kaposi's sarcoma in black South Africans in KwaZulu- Natal, South Africa (1983-2006). Int J STD AIDS. 2009; 20: 553-556.
  • 11
    Parkin DM, Sitas F, Chirenje M, et al. Part I: cancer in indigenous Africans-burden, distribution, and trends. Lancet Oncol. 2008; 9: 683-692.
  • 12
    Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998; 16: 2445-2451.
  • 13
    Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol. 1998; 16: 683-691.
  • 14
    Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996; 14: 2353-2364.
  • 15
    Martin-Carbonero L, Barrios A, Saballs P, et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS. 2004; 18: 1737-1740.
  • 16
    Tulpule A, Groopman J, Saville MW, et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer. 2002; 95: 147-154.
  • 17
    Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol. 1998; 16: 1112-1121.
  • 18
    Cianfrocca M, Cooley TP, Lee JY, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS Malignancy Consortium study. J Clin Oncol. 2002; 20: 153-159.
  • 19
    Cella DF, McCain NL, Peterman AH, et al. Development and validation of the Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) quality of life instrument. Qual Life Res. 1996; 5: 450-453.
  • 20
    Peterman AH, Cella D, Mo F, et al. Psychometric validation of the revised Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) quality of life instrument. Qual Life Res. 1997; 6: 572-584.
  • 21
    Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993; 11: 570-579.
  • 22
    Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response and staging criteria. J Clin Oncol. 1989; 7: 1201-1207.
  • 23
    O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979; 35: 549-556.
  • 24
    Brookmeyer R, Crowley JJ. A confidence interval for the median survival time. Biometrics. 1982; 38: 29-41.
  • 25
    Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987; 317: 192-197.
  • 26
    Blum L, Pellet C, Agbalika F, et al. Complete remission of AIDS-related Kaposi's sarcoma associated with undetectable human herpesvirus-8 sequences during anti-HIV protease therapy. AIDS. 1997; 11: 1653-1655.
  • 27
    Murphy M, Armstrong D, Sepkowitz KA, et al. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor. AIDS. 1997; 11: 261-262.
  • 28
    Martinelli C, Zazzi M, Ambu S, et al. Complete regression of AIDS-related Kaposi's sarcoma-associated human herpesvirus-8 during therapy with indinavir. AIDS. 1998; 12: 1717-1719.
  • 29
    Shaw A, McLean K. Kaposi sarcoma regression following treatment with a triple antiretroviral regimen containing nevaripine. Int J STD AIDS. 1999; 10: 417-418.
  • 30
    Niehues T, Horneff G, Megahed M, et al. Complete regression of AIDS-related Kaposi's sarcoma in AIDS. AIDS. 1999; 13: 1148-1149.
  • 31
    Murdaca G, Campelli A, Setti M, et al. Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of 2 nucleoside reverse transcriptase inhibitors and 1 non-nucleoside reverse transcriptase inhibitor. AIDS. 2002; 16: 304-305.
  • 32
    Osoba D, Northfelt DW, Budd DW, et al. Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: a randomized trial of pegylated liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine. Cancer Invest. 2001; 19: 573-580.